SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'EP5'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A)	1.09A	2y00A-6g79S: 28.3	2y00A-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.84A	2y00A-6g79S: 28.3	2y00A-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A)	1.12A	2y00B-6g79S: 28.3	2y00B-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.82A	2y00B-6g79S: 28.3	2y00B-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	7 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TRP S 356 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) None EP5 S 401 ( 4.9A)	1.06A	2y01A-6g79S: 28.2	2y01A-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.80A	2y01B-6g79S: 28.2	2y01B-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	1.14A	2y01B-6g79S: 28.2	2y01B-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.79A	2y03A-6g79S: 28.3	2y03A-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 ( 4.9A)	0.98A	2y03A-6g79S: 28.3	2y03A-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.76A	2y03B-6g79S: 28.2	2y03B-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 ( 4.9A)	0.98A	2y03B-6g79S: 28.2	2y03B-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y04_A_68HA601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 11	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.74A	2y04A-6g79S: 28.1	2y04A-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y04_A_68HA601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 11	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	1.13A	2y04A-6g79S: 28.1	2y04A-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y04_B_68HB601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.65A	2y04B-6g79S: 28.2	2y04B-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y04_B_68HB601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	1.09A	2y04B-6g79S: 28.2	2y04B-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3D4S_A_TIMA401_1 (BETA-2 ADRENERGIC RECEPTOR/T4-LYSOZYME CHIMERA)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 TRP S 327 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) None EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.58A	3d4sA-6g79S: 27.9	3d4sA-6g79S: 9.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3NYA_A_JTZA1203_1 (BETA-2 ADRENERGIC RECEPTOR, LYSOZYME)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.64A	3nyaA-6g79S: 27.8	3nyaA-6g79S: 9.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3NYA_A_JTZA1203_1 (BETA-2 ADRENERGIC RECEPTOR, LYSOZYME)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	1.00A	3nyaA-6g79S: 27.8	3nyaA-6g79S: 9.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3RZE_A_D7VA1201_1 (HISTAMINE H1 RECEPTOR, LYSOZYME CHIMERA)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	ASP S 129 THR S 134 TRP S 327 PHE S 331 TYR S 359	EP5 S 401 (-3.3A) EP5 S 401 (-3.8A) None EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.83A	3rzeA-6g79S: 28.0	3rzeA-6g79S: 19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AMJ_A_CVDA1359_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	1.17A	4amjA-6g79S: 28.2	4amjA-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AMJ_A_CVDA1359_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	7 / 12	TRP S 125 ASP S 129 SER S 212 TRP S 327 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) None EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.70A	4amjA-6g79S: 28.2	4amjA-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AMJ_B_CVDB1360_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	1.16A	4amjB-6g79S: 28.4	4amjB-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AMJ_B_CVDB1360_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	7 / 12	TRP S 125 ASP S 129 SER S 212 TRP S 327 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) None EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.68A	4amjB-6g79S: 28.4	4amjB-6g79S: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AWU_A_4CHA502_0 (OXIDOREDUCTASE, FMN-BINDING)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	4 / 7	THR S 355 TYR S 109 LEU S 126 PHE S 330	None None None EP5 S 401 (-4.0A)	1.35A	4awuA-6g79S: undetectable	4awuA-6g79S: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	ALA S 216 TRP S 327 PHE S 330 PHE S 331 PHE S 351	EP5 S 401 ( 4.0A) None EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 (-4.5A)	1.07A	4iaqA-6g79S: 34.2	4iaqA-6g79S: 95.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	9 / 12	LEU S 126 ASP S 129 CYH S 133 VAL S 201 ALA S 216 TRP S 327 PHE S 330 PHE S 331 THR S 355	None EP5 S 401 (-3.3A) EP5 S 401 (-4.2A) EP5 S 401 (-4.1A) EP5 S 401 ( 4.0A) None EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) None	0.63A	4iaqA-6g79S: 34.2	4iaqA-6g79S: 95.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	4 / 6	TRP S 125 ILE S 130 THR S 134 SER S 212	None EP5 S 401 (-4.2A) EP5 S 401 (-3.8A) EP5 S 401 (-3.3A)	0.72A	4iaqA-6g79S: 34.2	4iaqA-6g79S: 95.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4IAR_A_ERMA2001_1 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	CYH S 133 TRP S 327 PHE S 330 MET S 337 THR S 355	EP5 S 401 (-4.2A) None EP5 S 401 (-4.0A) EP5 S 401 (-4.0A) None	1.50A	4iarA-6g79S: 34.6	4iarA-6g79S: 95.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4IAR_A_ERMA2001_1 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	8 / 12	LEU S 126 ASP S 129 CYH S 133 VAL S 201 ALA S 216 TRP S 327 PHE S 330 THR S 355	None EP5 S 401 (-3.3A) EP5 S 401 (-4.2A) EP5 S 401 (-4.1A) EP5 S 401 ( 4.0A) None EP5 S 401 (-4.0A) None	0.62A	4iarA-6g79S: 34.6	4iarA-6g79S: 95.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4IAR_A_ERMA2001_1 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	7 / 12	LEU S 126 ASP S 129 CYH S 133 VAL S 201 ALA S 216 TRP S 327 SER S 334	None EP5 S 401 (-3.3A) EP5 S 401 (-4.2A) EP5 S 401 (-4.1A) EP5 S 401 ( 4.0A) None EP5 S 401 (-3.6A)	0.81A	4iarA-6g79S: 34.6	4iarA-6g79S: 95.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4IAR_A_ERMA2001_2 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	4 / 7	TRP S 125 ILE S 130 SER S 212 PHE S 331	None EP5 S 401 (-4.2A) EP5 S 401 (-3.3A) EP5 S 401 (-4.7A)	0.74A	4iarA-6g79S: 34.6	4iarA-6g79S: 95.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4IAR_A_ERMA2001_2 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	4 / 7	TRP S 125 ILE S 130 THR S 134 PHE S 331	None EP5 S 401 (-4.2A) EP5 S 401 (-3.8A) EP5 S 401 (-4.7A)	0.43A	4iarA-6g79S: 34.6	4iarA-6g79S: 95.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4IB4_A_ERMA2001_1 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	LEU S 126 ALA S 216 TRP S 327 PHE S 330 PHE S 331	None EP5 S 401 ( 4.0A) None EP5 S 401 (-4.0A) EP5 S 401 (-4.7A)	0.50A	4ib4A-6g79S: 28.1	4ib4A-6g79S: 19.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4NC3_A_ERMA1202_1 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	LEU S 126 ASP S 129 ALA S 216 TRP S 327 PHE S 330	None EP5 S 401 (-3.3A) EP5 S 401 ( 4.0A) None EP5 S 401 (-4.0A)	0.53A	4nc3A-6g79S: 28.8	4nc3A-6g79S: 19.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5TUD_A_ERMA2001_1 (5-HYDROXYTRYPTAMINE RECEPTOR 2B,SOLUBLE CYTOCHROME B562 CHIMERA)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	LEU S 126 ASP S 129 ALA S 216 PHE S 330 PHE S 331	None EP5 S 401 (-3.3A) EP5 S 401 ( 4.0A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A)	0.45A	5tudA-6g79S: 30.4	5tudA-6g79S: 21.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6A93_A_8NUA3001_0 (5-HYDROXYTRYPTAMINE RECEPTOR 2A,SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	7 / 12	SER S 106 TRP S 125 THR S 134 TRP S 327 PHE S 330 PHE S 331 TYR S 359	None None EP5 S 401 (-3.8A) None EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.81A	6a93A-6g79S: 24.9	6a93A-6g79S: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6A93_A_8NUA3001_0 (5-HYDROXYTRYPTAMINE RECEPTOR 2A,SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	THR S 134 PHE S 323 TRP S 327 PHE S 330 PHE S 331	EP5 S 401 (-3.8A) None None EP5 S 401 (-4.0A) EP5 S 401 (-4.7A)	1.34A	6a93A-6g79S: 24.9	6a93A-6g79S: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6A93_B_8NUB3001_0 (5-HYDROXYTRYPTAMINE RECEPTOR 2A,SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	SER S 106 TRP S 125 THR S 134 PHE S 330 PHE S 331	None None EP5 S 401 (-3.8A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A)	0.79A	6a93B-6g79S: 26.4	6a93B-6g79S: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6A93_B_8NUB3001_0 (5-HYDROXYTRYPTAMINE RECEPTOR 2A,SOLUBLE CYTOCHROME B562)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	SER S 106 TRP S 125 TRP S 327 PHE S 330 PHE S 331	None None None EP5 S 401 (-4.0A) EP5 S 401 (-4.7A)	0.72A	6a93B-6g79S: 26.4	6a93B-6g79S: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6CM4_A_8NUA2001_0 (D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	CYH S 133 THR S 134 PHE S 331 TYR S 109 TYR S 359	EP5 S 401 (-4.2A) EP5 S 401 (-3.8A) EP5 S 401 (-4.7A) None EP5 S 401 ( 4.9A)	1.34A	6cm4A-6g79S: 25.8	6cm4A-6g79S: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6CM4_A_8NUA2001_0 (D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	CYH S 133 THR S 134 TRP S 327 THR S 355 TYR S 359	EP5 S 401 (-4.2A) EP5 S 401 (-3.8A) None None EP5 S 401 ( 4.9A)	0.82A	6cm4A-6g79S: 25.8	6cm4A-6g79S: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6CM4_A_8NUA2001_0 (D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	CYH S 133 TRP S 327 PHE S 331 THR S 355 TYR S 359	EP5 S 401 (-4.2A) None EP5 S 401 (-4.7A) None EP5 S 401 ( 4.9A)	0.90A	6cm4A-6g79S: 25.8	6cm4A-6g79S: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6DRX_A_H8GA1201_0 (5HT2B RECEPTOR, BRIL CHIMERA)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	LEU S 126 THR S 134 ALA S 216 TRP S 327 PHE S 330 TYR S 359	None EP5 S 401 (-3.8A) EP5 S 401 ( 4.0A) None EP5 S 401 (-4.0A) EP5 S 401 ( 4.9A)	0.60A	6drxA-6g79S: 28.9	6drxA-6g79S: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6DRX_A_H8GA1201_0 (5HT2B RECEPTOR, BRIL CHIMERA)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 LEU S 126 THR S 134 ALA S 216 TRP S 327 TYR S 359	None None EP5 S 401 (-3.8A) EP5 S 401 ( 4.0A) None EP5 S 401 ( 4.9A)	0.58A	6drxA-6g79S: 28.9	6drxA-6g79S: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6DRY_A_H8DA2001_0 (5HT2B RECEPTOR, BRIL CHIMERA)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 11	ASP S 129 THR S 134 ALA S 216 PHE S 330 TYR S 359	EP5 S 401 (-3.3A) EP5 S 401 (-3.8A) EP5 S 401 ( 4.0A) EP5 S 401 (-4.0A) EP5 S 401 ( 4.9A)	0.45A	6dryA-6g79S: 26.5	6dryA-6g79S: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.75A	6h7jA-6g79S: 32.5	6h7jA-6g79S: 29.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.75A	6h7jB-6g79S: 33.1	6h7jB-6g79S: 29.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7M_A_68HA504_0 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.76A	6h7mA-6g79S: 32.7	6h7mA-6g79S: 29.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7M_B_68HB405_0 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5 S 401 (-3.3A) EP5 S 401 (-3.3A) EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.76A	6h7mB-6g79S: 33.0	6h7mB-6g79S: 29.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6IBL_A_H98A501_0 (THIOREDOXIN 1,BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	TRP S 125 TRP S 327 PHE S 330 PHE S 331 TYR S 359	None None EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.51A	6iblA-6g79S: 23.9	6iblA-6g79S: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6IBL_B_H98B501_0 (THIOREDOXIN 1,BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	TRP S 125 TRP S 327 PHE S 330 PHE S 331 TYR S 359	None None EP5 S 401 (-4.0A) EP5 S 401 (-4.7A) EP5 S 401 ( 4.9A)	0.55A	6iblB-6g79S: 32.6	6iblB-6g79S: undetectable

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["2Y00_A_Y00A601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A)","1.09A","2y00A-6g79S:28.3",null],["2Y00_A_Y00A601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.84A","2y00A-6g79S:28.3","2y00A-6g79S:14.22"],["2Y00_B_Y00B601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A)","1.12A","2y00B-6g79S:28.3","2y00A-6g79S:14.22"],["2Y00_B_Y00B601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.82A","2y00B-6g79S:28.3","2y00B-6g79S:14.22"],["2Y01_A_Y00A601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",7,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TRP S 356;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);None;EP5 S 401 ( 4.9A)","1.06A","2y01A-6g79S:28.2","2y00B-6g79S:14.22"],["2Y01_B_Y00B601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.80A","2y01B-6g79S:28.2","2y01A-6g79S:14.22"],["2Y01_B_Y00B601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","1.14A","2y01B-6g79S:28.2","2y01B-6g79S:14.22"],["2Y03_A_5FWA601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.79A","2y03A-6g79S:28.3","2y01B-6g79S:14.22"],["2Y03_A_5FWA601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"TRP S 125;ASP S 129;SER S 212;PHE S 330;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 ( 4.9A)","0.98A","2y03A-6g79S:28.3","2y03A-6g79S:14.22"],["2Y03_B_5FWB601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.76A","2y03B-6g79S:28.2","2y03A-6g79S:14.22"],["2Y03_B_5FWB601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"TRP S 125;ASP S 129;SER S 212;PHE S 330;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 ( 4.9A)","0.98A","2y03B-6g79S:28.2","2y03B-6g79S:14.22"],["2Y04_A_68HA601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.74A","2y04A-6g79S:28.1","2y03B-6g79S:14.22"],["2Y04_A_68HA601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","1.13A","2y04A-6g79S:28.1","2y04A-6g79S:14.22"],["2Y04_B_68HB601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.65A","2y04B-6g79S:28.2","2y04A-6g79S:14.22"],["2Y04_B_68HB601_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","1.09A","2y04B-6g79S:28.2","2y04B-6g79S:14.22"],["3D4S_A_TIMA401_1","BETA-2 ADRENERGIC RECEPTOR\/T4-LYSOZYME CHIMERA","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;TRP S 327;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);None;EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.58A","3d4sA-6g79S:27.9","2y04B-6g79S:14.22"],["3NYA_A_JTZA1203_1","BETA-2 ADRENERGIC RECEPTOR, LYSOZYME","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.64A","3nyaA-6g79S:27.8","3d4sA-6g79S:9.93"],["3NYA_A_JTZA1203_1","BETA-2 ADRENERGIC RECEPTOR, LYSOZYME","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","1.00A","3nyaA-6g79S:27.8","3nyaA-6g79S:9.93"],["3RZE_A_D7VA1201_1","HISTAMINE H1 RECEPTOR, LYSOZYME CHIMERA","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"ASP S 129;THR S 134;TRP S 327;PHE S 331;TYR S 359","EP5 S 401 (-3.3A);EP5 S 401 (-3.8A);None;EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.83A","3rzeA-6g79S:28.0","3nyaA-6g79S:9.93"],["4AMJ_A_CVDA1359_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","1.17A","4amjA-6g79S:28.2","3rzeA-6g79S:19.10"],["4AMJ_A_CVDA1359_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",7,"TRP S 125;ASP S 129;SER S 212;TRP S 327;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);None;EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.70A","4amjA-6g79S:28.2","4amjA-6g79S:14.22"],["4AMJ_B_CVDB1360_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","1.16A","4amjB-6g79S:28.4","4amjA-6g79S:14.22"],["4AMJ_B_CVDB1360_1","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",7,"TRP S 125;ASP S 129;SER S 212;TRP S 327;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);None;EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.68A","4amjB-6g79S:28.4","4amjB-6g79S:14.22"],["4AWU_A_4CHA502_0","OXIDOREDUCTASE, FMN-BINDING","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",4,"THR S 355;TYR S 109;LEU S 126;PHE S 330","None;None;None;EP5 S 401 (-4.0A)","1.35A","4awuA-6g79S:undetectable","4amjB-6g79S:14.22"],["4IAQ_A_2GMA2001_1","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"ALA S 216;TRP S 327;PHE S 330;PHE S 331;PHE S 351","EP5 S 401 ( 4.0A);None;EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 (-4.5A)","1.07A","4iaqA-6g79S:34.2","4awuA-6g79S:undetectable"],["4IAQ_A_2GMA2001_1","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",9,"LEU S 126;ASP S 129;CYH S 133;VAL S 201;ALA S 216;TRP S 327;PHE S 330;PHE S 331;THR S 355","None;EP5 S 401 (-3.3A);EP5 S 401 (-4.2A);EP5 S 401 (-4.1A);EP5 S 401 ( 4.0A);None;EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);None","0.63A","4iaqA-6g79S:34.2","4iaqA-6g79S:95.18"],["4IAQ_A_2GMA2001_2","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",4,"TRP S 125;ILE S 130;THR S 134;SER S 212","None;EP5 S 401 (-4.2A);EP5 S 401 (-3.8A);EP5 S 401 (-3.3A)","0.72A","4iaqA-6g79S:34.2","4iaqA-6g79S:95.18"],["4IAR_A_ERMA2001_1","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"CYH S 133;TRP S 327;PHE S 330;MET S 337;THR S 355","EP5 S 401 (-4.2A);None;EP5 S 401 (-4.0A);EP5 S 401 (-4.0A);None","1.50A","4iarA-6g79S:34.6","4iaqA-6g79S:95.18"],["4IAR_A_ERMA2001_1","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",8,"LEU S 126;ASP S 129;CYH S 133;VAL S 201;ALA S 216;TRP S 327;PHE S 330;THR S 355","None;EP5 S 401 (-3.3A);EP5 S 401 (-4.2A);EP5 S 401 (-4.1A);EP5 S 401 ( 4.0A);None;EP5 S 401 (-4.0A);None","0.62A","4iarA-6g79S:34.6","4iarA-6g79S:95.18"],["4IAR_A_ERMA2001_1","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",7,"LEU S 126;ASP S 129;CYH S 133;VAL S 201;ALA S 216;TRP S 327;SER S 334","None;EP5 S 401 (-3.3A);EP5 S 401 (-4.2A);EP5 S 401 (-4.1A);EP5 S 401 ( 4.0A);None;EP5 S 401 (-3.6A)","0.81A","4iarA-6g79S:34.6","4iarA-6g79S:95.18"],["4IAR_A_ERMA2001_2","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",4,"TRP S 125;ILE S 130;SER S 212;PHE S 331","None;EP5 S 401 (-4.2A);EP5 S 401 (-3.3A);EP5 S 401 (-4.7A)","0.74A","4iarA-6g79S:34.6","4iarA-6g79S:95.18"],["4IAR_A_ERMA2001_2","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",4,"TRP S 125;ILE S 130;THR S 134;PHE S 331","None;EP5 S 401 (-4.2A);EP5 S 401 (-3.8A);EP5 S 401 (-4.7A)","0.43A","4iarA-6g79S:34.6","4iarA-6g79S:95.18"],["4IB4_A_ERMA2001_1","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"LEU S 126;ALA S 216;TRP S 327;PHE S 330;PHE S 331","None;EP5 S 401 ( 4.0A);None;EP5 S 401 (-4.0A);EP5 S 401 (-4.7A)","0.50A","4ib4A-6g79S:28.1","4iarA-6g79S:95.18"],["4NC3_A_ERMA1202_1","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"LEU S 126;ASP S 129;ALA S 216;TRP S 327;PHE S 330","None;EP5 S 401 (-3.3A);EP5 S 401 ( 4.0A);None;EP5 S 401 (-4.0A)","0.53A","4nc3A-6g79S:28.8","4ib4A-6g79S:19.77"],["5TUD_A_ERMA2001_1","5-HYDROXYTRYPTAMINE RECEPTOR 2B,SOLUBLE CYTOCHROME B562 CHIMERA","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"LEU S 126;ASP S 129;ALA S 216;PHE S 330;PHE S 331","None;EP5 S 401 (-3.3A);EP5 S 401 ( 4.0A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A)","0.45A","5tudA-6g79S:30.4","4nc3A-6g79S:19.77"],["6A93_A_8NUA3001_0","5-HYDROXYTRYPTAMINE RECEPTOR 2A,SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",7,"SER S 106;TRP S 125;THR S 134;TRP S 327;PHE S 330;PHE S 331;TYR S 359","None;None;EP5 S 401 (-3.8A);None;EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.81A","6a93A-6g79S:24.9","5tudA-6g79S:21.47"],["6A93_A_8NUA3001_0","5-HYDROXYTRYPTAMINE RECEPTOR 2A,SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"THR S 134;PHE S 323;TRP S 327;PHE S 330;PHE S 331","EP5 S 401 (-3.8A);None;None;EP5 S 401 (-4.0A);EP5 S 401 (-4.7A)","1.34A","6a93A-6g79S:24.9","6a93A-6g79S:undetectable"],["6A93_B_8NUB3001_0","5-HYDROXYTRYPTAMINE RECEPTOR 2A,SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"SER S 106;TRP S 125;THR S 134;PHE S 330;PHE S 331","None;None;EP5 S 401 (-3.8A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A)","0.79A","6a93B-6g79S:26.4","6a93A-6g79S:undetectable"],["6A93_B_8NUB3001_0","5-HYDROXYTRYPTAMINE RECEPTOR 2A,SOLUBLE CYTOCHROME B562","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"SER S 106;TRP S 125;TRP S 327;PHE S 330;PHE S 331","None;None;None;EP5 S 401 (-4.0A);EP5 S 401 (-4.7A)","0.72A","6a93B-6g79S:26.4","6a93B-6g79S:undetectable"],["6CM4_A_8NUA2001_0","D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"CYH S 133;THR S 134;PHE S 331;TYR S 109;TYR S 359","EP5 S 401 (-4.2A);EP5 S 401 (-3.8A);EP5 S 401 (-4.7A);None;EP5 S 401 ( 4.9A)","1.34A","6cm4A-6g79S:25.8","6a93B-6g79S:undetectable"],["6CM4_A_8NUA2001_0","D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"CYH S 133;THR S 134;TRP S 327;THR S 355;TYR S 359","EP5 S 401 (-4.2A);EP5 S 401 (-3.8A);None;None;EP5 S 401 ( 4.9A)","0.82A","6cm4A-6g79S:25.8","6cm4A-6g79S:undetectable"],["6CM4_A_8NUA2001_0","D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"CYH S 133;TRP S 327;PHE S 331;THR S 355;TYR S 359","EP5 S 401 (-4.2A);None;EP5 S 401 (-4.7A);None;EP5 S 401 ( 4.9A)","0.90A","6cm4A-6g79S:25.8","6cm4A-6g79S:undetectable"],["6DRX_A_H8GA1201_0","5HT2B RECEPTOR, BRIL CHIMERA","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"LEU S 126;THR S 134;ALA S 216;TRP S 327;PHE S 330;TYR S 359","None;EP5 S 401 (-3.8A);EP5 S 401 ( 4.0A);None;EP5 S 401 (-4.0A);EP5 S 401 ( 4.9A)","0.60A","6drxA-6g79S:28.9","6cm4A-6g79S:undetectable"],["6DRX_A_H8GA1201_0","5HT2B RECEPTOR, BRIL CHIMERA","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;LEU S 126;THR S 134;ALA S 216;TRP S 327;TYR S 359","None;None;EP5 S 401 (-3.8A);EP5 S 401 ( 4.0A);None;EP5 S 401 ( 4.9A)","0.58A","6drxA-6g79S:28.9","6drxA-6g79S:undetectable"],["6DRY_A_H8DA2001_0","5HT2B RECEPTOR, BRIL CHIMERA","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"ASP S 129;THR S 134;ALA S 216;PHE S 330;TYR S 359","EP5 S 401 (-3.3A);EP5 S 401 (-3.8A);EP5 S 401 ( 4.0A);EP5 S 401 (-4.0A);EP5 S 401 ( 4.9A)","0.45A","6dryA-6g79S:26.5","6drxA-6g79S:undetectable"],["6H7J_A_5FWA401_0","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.75A","6h7jA-6g79S:32.5","6dryA-6g79S:undetectable"],["6H7J_B_5FWB402_0","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.75A","6h7jB-6g79S:33.1","6h7jA-6g79S:29.79"],["6H7M_A_68HA504_0","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.76A","6h7mA-6g79S:32.7","6h7jB-6g79S:29.79"],["6H7M_B_68HB405_0","BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",6,"TRP S 125;ASP S 129;SER S 212;PHE S 330;PHE S 331;TYR S 359","None;EP5 S 401 (-3.3A);EP5 S 401 (-3.3A);EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.76A","6h7mB-6g79S:33.0","6h7mA-6g79S:29.79"],["6IBL_A_H98A501_0","THIOREDOXIN 1,BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"TRP S 125;TRP S 327;PHE S 330;PHE S 331;TYR S 359","None;None;EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.51A","6iblA-6g79S:23.9","6h7mB-6g79S:29.79"],["6IBL_B_H98B501_0","THIOREDOXIN 1,BETA-1 ADRENERGIC RECEPTOR","6g79","5-HYDROXYTRYPTAMINE RECEPTOR 1B","Homo sapiens",5,"TRP S 125;TRP S 327;PHE S 330;PHE S 331;TYR S 359","None;None;EP5 S 401 (-4.0A);EP5 S 401 (-4.7A);EP5 S 401 ( 4.9A)","0.55A","6iblB-6g79S:32.6","6iblA-6g79S:undetectable"]]